Stay updated with breaking news from Ryan Sullivan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The mRNA cancer vaccine combined with immunotherapy improved survival rates for stage 3 and 4 melanoma, Moderna and Merck announced. Here's what to know.
By Julie Steenhuysen and Michael Erman (Reuters) - An experimental mRNA vaccine developed by Moderna Inc combined with Merck & Co's blockbuster immuno...
The combination of an experimental mRNA vaccine with an immunotherapy reduced the likelihood of melanoma recurring or causing death by 44% when compared to immunotherapy alone, a new clinical trial shows.
An experimental mRNA cancer vaccine developed by Moderna Inc and Merck & Co cut the risk of death or recurrence of the most deadly skin cancer by 44% compared with Merck's immunotherapy Keytruda... | April 16, 2023
MRNA-4157 in combination with pembrolizumab improved recurrence-free survival compared with pembrolizumab alone when used as an adjuvant treatment in patients with resected high-risk melanoma, regardless of tumor mutational burden.